Giant Cell Arteritis
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
In post hoc analysis of patients who achieved clinical remission in the double-blind 52-week part 1 of the GiACTA trial and maintained treatment-free clinical remission throughout the 2-year open-label part 2, those who recieved tocilizumab in part 1 maintained statistically significant and clinically relevant improvements in the SF-36 mental component summary compared with those who recieved placebo in part 1. Patients who recived at least one dose of tocilizmab over the entire 3-year study period appeared to experience greater improvements than patients who never received tocilizumab. This suggests that patients with GCA who achieve remission with tocilizumab treatment could potentially extend the benefits they experience in health-related quality of life, even after tocilizumab is discontinued.
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in the GiACTA Trial
This posthoc analysis of the GiACTA trial compared the efficacy of tocilizumab vs placebo in patients with giant cell arteritis (GCA) who had polymyalgia rheumatica (PMR) symptoms only (no cranial symptoms) or cranial symptoms only (no PMR symtpoms) at the time of GCA diagnosis. Baseline characteristics, sustained remission, number and rate of flares, cumulative prednisone dose and safety were assessed.
Long-Term Outcome of Tocilizumab For Patients With Giant Cell Arteritis: Results From Part 2 of the GiACTA Trial
Patients treated with tocilizumab in the 1-year double-blind period of the GiACTA trial maintained clinical remission and had lower glucocorticoid exposure during the 2-year, open-label long-term extension. Patients originally assigned to tocilizumab were more likely to maintain clinical remission after withdrawal of GCA treatment than those originally assigned to placebo, and patients who experienced GCA flare had clinical remission restored if they restarted TCZ.
ARVO 2019 poster: Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
This is a retrospective medical chart review of patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) at a single center from 2010 to 2018. The incidence of flares, time to flare, and the incidence of flares with visual manifestations were assessed before and after TCZ initiation and in patients with or without visual manifestations at GCA diagnosis.
EULAR 2019 poster: Treatment Patterns, Disease Burden and Outcomes in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica
This retrospective cohort study used electronic medical records from a single US community-based rheumatology clinic to assess patterns of glucocorticoid use and outcomes in patients with giant cell arteritis (GCA), polymyalgia rheumatica (PMR) or both. Outcomes at 2 years included proportion of patients achieving remission, persistence of remission and prednisone dose at follow-up, and results were compared between patients with GCA only, PMR only or both GCA and PMR.
EULAR 2019 poster: Risk Factors for Treatment Failure in Patients With Giant Cell Arteritis Treated With ▼Tocilizumab Plus Prednisone Versus Prednisone Alone
This multivariate analysis of data from the GiACTA trial of ▼tocilizumab in giant cell arteritis identified that patients treated with prednisone alone were more likely to experience treatment failure than those treated with tocilizumab plus prednisone. Females were more likely to experience treatment failure than males when treated with prednisone alone but not if they received ▼tocilizumab as well. Worse quality of life, lower prednisone dose, and some clinical symptoms were associated with treatment failure in tocilizumab-treated
EULAR 2019: Clinical Outcomes of Patients With Giant Cell Arteritis With Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated With ▼Tocilizumab or Placebo in the GiACTA Trial
This posthoc analysis of the GiACTA trial compared the efficacy of ▼tocilizumab vs placebo in patients with giant cell arteritis (GCA) who had polymyalgia rheumatica (PMR) symptoms only (no cranial symptoms) or cranial symptoms only (no PMR symptoms) at the time of GCA diagnosis. Baseline characteristics, sustained remission, number and rate of flares, cumulative prednisone dose and safety were assessed.
Vasculitis presentation 2019: Risk Factors for Treatment Failure in Patients With Giant Cell Arteritis Treated With Tocilizumab Plus Prednisone Versus Prednisone Alone
Risk factors for treatment failure (failure to achieve sustained remission) were investigated in a post hoc univariate analysis of data from the GiACTA trial of tocilizumab versus placebo in patients with giant cell arteritis (GCA). The risk for treatment failure was higher for women than men with GCA treated with prednisone alone but this effect of gender was not evident for patients who received tocilizumab added to prednisone treatment. Impaired health-related quality of life at baseline was predictive of treatment failure in tocilizumab-treated patients and patients who received placebo plus prednisone.
Vasculitis poster 2019: Risk of Potential Glucocorticoid-related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
This retrospective, observational study used electronic health records of US patients with giant cell arteritis (GCA) who received oral glucocorticoids (OGCs) within 6 months of GCA diagnosis between 2009 and 2015. Potential adverse events (AEs) were assesed during the 12 months post index (date of first OGC prescription) and descriptively summarized across 4 quartiles of OGC daily dose.
Vasculitis poster 2019: Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomized controlled trial
The effects of baseline prednisone doses on disease flare and sustained remission in patients from the GiACTA trial of tocilizumab versus placebo in patients with giant cell arteritis (GCA) were investigated in post hoc analyses. Fewer patients who received tocilizumab experienced GCA flare than those who received placebo and most patients who experienced flare were receiving concomitant glucocorticoids at the time of flare. Tocilizumab-treated patients achieved sustained remission across the range of baseline prednisone doses (20 – 60 mg/day) and had similar time to flare regardless of baseline prednisone dose.
Epidemiology, Clinical Presentation and Clinical Sequelae of Giant Cell Arteritis
Test your knowledge of epidemiology, clinical presentation and clinical sequelae of Giant Cell Arteritis with this interactive quiz. Follow this link to take the quiz.